

III. Claims 20, 31-34, 54, 56-58, and 62, drawn to recombinant RSV with heterologous RSV genes, classified in Class 424, subclass 199.1 and to claims 1, 11, 47-51, and 61 to the extent that they read on claims 20, 31-34, 54, 56-58, and 62.

IV. Claims 21, 35, and 59, drawn to recombinant RSV with genome modifications to encode non-RSV proteins, classified in Class 424, subclass 199.1 and to claims 1, 26, and 47-51 to the extent that they read on claims 21, 35, and 59.

V. Claim 19, drawn to recombinant RSV with a nucleotide modification in a translational start codon, classified in class 424, subclass 199.1 and to claims 1 and 11 to the extent that they read on claim 19.

VI. Claims 18 and 38, drawn to recombinant RSV with a nucleotide modification in a termination codon or a GS or GE transcription signal, classified in class 424, subclass 199.1 and to claims 1 and 11 to the extent that they read on claims 18 and 38.

VII. Claims 22-25, 36, 37, and 60, drawn to recombinant RSV with a parainfluenza (PIV) gene classified in class 424, subclass 199.1 and to claims 1, 11, 30, 47-51, 54, and 55 to the extent that they read on claims 22-25, 30, 36, 37, and 60.

VIII. Claims 15-17, 29, 30, and 54 drawn to recombinant RSV with a nucleotide modification to a cis-acting regulatory sequence classified in class 424, subclass 199.1 and to claims 1, 11, 30, 47-51, and 55 to the extent that they read on claims 15-17, 29, 30, and 54.

IX. Claims 39-46, drawn to a vaccine and methods of stimulating the immune system, classified in class 199.1, subclass 199.1 and to claims 26 and 38 to the extent that they read on claims 39-46.

Applicants elect to prosecute Group I, claims 2-10.